What should a new thrombolytic bring us?
Verheugt
F
F
Department of Cardiology, Academisch Ziekenhuis Nijmegen, The Netherlands.
D002543:Cerebral Hemorrhage / Q000209:etiology; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000379:methods*
D005343:Fibrinolytic Agents